[Prevention of HPV-induced diseases by prophylactic vaccination].

Abstract

Human papillomavirus (HPV) infections belong to the most frequent viral infections. Besides benign common warts and benign and malignant lesions of the head and neck area, HPV can induce anogenital dysplasias and cancers. Since the year 2007, effective and safe prophylactic HPV vaccines are licensed in Europe. To date, a bivalent (HPV16 and 18) and a nonavalent HPV vaccine (HPV6, 11, 16, 18, 31, 33, 45, 52, and 58) are commercially available in Germany. The German standing committee on vaccination (STIKO) currently recommends gender-neutral prophylactic HPV-vaccination between 9 and 14 years of age, with the possibility of catch-up vaccination until the age of 17 years. Besides a large proportion of HPV-induced anogenital dysplasias and carcinomas, the nonavalent HPV vaccine also prevents anogenital warts. Iatrogenically immunocompromised patients older than 17 years of age should also receive prophylactic HPV vaccination, preferrably by the age of 26 years. In case of already acquired HPV infection or existing HPV-induced lesions prophylactic vaccination does not lead to accelerated HPV elimination or clearance of lesions.

• Authors: Ulrike Wieland, Alexander Kreuter
• Journal: Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete (Hautarzt) Vol. 72 Issue 2 Pg. 106-113 (Feb 2021) ISSN: 1432-1173 [Electronic] Germany
• Vernacular Title: Prävention HPV-induzierter Erkrankungen durch prophylaktische Impfung.
• PMID: 33337514 (Publication Type: Journal Article, Review)

Chemical References

• Papillomavirus Vaccines

Topics

• Adolescent
• Adult
• Condylomata Acuminata
• Europe
• Germany
• Humans
• Papillomavirus Infections (prevention & control)
• Papillomavirus Vaccines
• Vaccination